Filing Flows › GeneDx Holdings (WGS) › Guidance & outlook

GeneDx Holdings (WGS) guidance and outlook

GeneDx Holdings' 10-Q filed Nov 9, 2026 makes 15 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• We believe several important factors have impacted, and will continue to impact, our performance and results of operations.
• We source, and will continue to source, components of our diagnostic testing workflows from third parties.
• To compete successfully, we must accurately anticipate technology developments and deliver innovative, relevant, and useful products, services, and technologies on time.
• We expect to incur significant expenses to advance these development efforts, but they may not be successful.
• With respect to existing collaboration and service agreements, our revenue may fluctuate period to period due to the pattern in which we may deliver our services, our ability to achieve milestones, the timing of costs incurred, changes in estimates of total anticipated costs that we expect to incur during the contract period, and other events that may not be within our control.
• We expect the cost of services to generally increase in absolute dollars with the anticipated growth in diagnostic testing volume and services we provide under our collaboration service agreements.
• However, we expect the cost per test to decrease over the long term due to the efficiencies we may gain from improved utilization of our laboratory capacity, automation, and other value engineering initiatives.
• These expected reductions may be offset by new tests which often have a higher cost per test during the introductory phases before we can gain efficiencies.
• We generally expect our research and development expenses to continue to increase in absolute dollars as we innovate and expand the application of our platforms.
• However, we expect research and development expenses to decrease as a percentage of revenue in the long term, although the percentage may fluctuate from period to period due to the timing and extent of our development and commercialization efforts and fluctuations in our compensation-related charges.
• We generally expect our selling, general and administrative expenses to continue to increase in absolute dollars as we expand our commercial sales, marketing and counseling teams, increase marketing activities, grow our administrative infrastructure, and incur costs associated with operating as a public company, including legal, accounting, regulatory, and Nasdaq and SEC compliance expenses.
• However, we expect selling, general and administrative expenses to decrease as a percentage of revenue over the long term as revenue increases, subject to fluctuations from period to period due to the timing and magnitude of these expenses and compensation-related charges.

GeneDx Holdings' latest quarter

Questions

What does GeneDx Holdings expect?

We believe several important factors have impacted, and will continue to impact, our performance and results of operations. We source, and will continue to source, components of our diagnostic testing workflows from third parties. To compete successfully, we must accurately anticipate technology developments and deliver innovative, relevant, and useful products, services, and technologies on time.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.